---
title: "Kvantify ApS – Regnskab 2025 og nøgletal"
description: "Kvantify ApS (CVR 42958093). Regnskabsperiode: 2025-01-01 – 2025-12-31. Bruttofortjeneste -20 mio. DKK, årets resultat -36,1 mio. DKK, egenkapital -5,1 mio. DKK."
canonical_url: "https://datapublica.dk/companies/42958093-kvantify-aps/financials"
locale: "da"
route_type: "company_financials"
robots: "index,follow"
content_access: "standard"
---

# Kvantify ApS — Regnskab

Kvantify ApS \(CVR 42958093\). Regnskabsperiode: 2025-01-01 – 2025-12-31. Bruttofortjeneste -20 mio. DKK, årets resultat -36,1 mio. DKK, egenkapital -5,1 mio. DKK.

CVR 42958093

## Seneste regnskabsperiode

- 2025 • 2025-01-01 • 2025-12-31 • entity • DKK • -20026078 • -40070827 • -36058924 • 37444306 • -5071143 • 37

## Regnskabshistorik

- 2024 • 2024-01-01 • 2024-12-31 • entity • DKK • -23919727 • -42453488 • -37501990 • 32782823 • 30987781 • 49

- 2023 • 2023-01-01 • 2023-12-31 • entity • DKK • -1586514 • -14585227 • -11442766 • 18292144 • -4275743 • 31

- 2022 • 2022-01-07 • 2022-12-31 • entity • DKK • -2581229 • -9054946 • -7452977 • 8178076 • 7167023 • 12

## Højdepunkter fra årsrapporten

- primary activities • Description of key activities of the companyThe company's purpose is to develop software to use high-performance computing and quantum computers to solve complex scientific and industrial challenges. The main products and services are related to chemical simulations, in particular towards the drug discovery process. • entity

- development in activities and financial affairs • Significant changes in the company's activities and financial mattersNet loss for the year totals DKK -36.059 thousand against DKK -37.502 thousand last year after allocation of the loss for the year, the total equity amounts to -5.071 thousands. Management considers the net loss as expected.

In 2025, the focus was primarily on product development and customer specific projects. The company's primary income going forward is expected to be driven by product sales and associated projects supplemented with grants.

The company has launched three products towards customers with the latest being their first quantum computing product called Qrunch. Their other two products are related to computational drug discovery called Koffee. All products are launched but ongoing improvements based on customer feedback and technological development are continuously implemented.

The company's liquidity and capital availability in 2026 will consist of already existing capital, new capital as well as already approved grants from various actors. The company's shareholders have entered into an agreement for the infusion of liquidity in early 2026.

As a start up that continues to invest in future growth, the company expects to increase its capital in 2026 through new investors as well as further investments from current investors.

The management considers the company's capital resources and dialogue with shareholders regarding new liquidity to be reassuring for the company's financial position. • entity

- subsequent events • Events occurring after the end of the financial yearThe company entered into an agreement for financing through convertible debt instruments at the beginning of 2026.

Furthermore, there have been no events after the end of the financial year that have a material impact on the financial statements. • entity

- contingent liabilities • 6.Contractual obligations and contingencies, etc.

Rent obligations:

The company has entered into tenancy agreements with a notice of termination of 6-12 months. The annual rent constitutes T.DKK. 2.946. The earliest dates on which the company can exit the lease contracts are the 31 March 2027 and 14 October 2027, and the total lease obligation as of 31 December 2025 amounts to T.DKK 4.872.

Lease agreementsThe company has entered into operational leases with an average annual lease payment of 15 t.dkk. The leases have 28 months to maturity and total outstanding lease payments total 36 t.dkk • entity